Pesquisar
Bicycle Therapeutics PLC
BCYCAdicionar à lista de desejos
4.360USD
-0.090-2.02%
Fechamento 05/18, 16:00（ET）Cotações atrasadas em 15 min
304.38MValor de mercado
PerdaP/L TTM
Mais detalhes de Bicycle Therapeutics PLC Empresa
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
Informações de Bicycle Therapeutics PLC
Código da empresaBCYC
Nome da EmpresaBicycle Therapeutics PLC
Data de listagemMay 23, 2019
CEOLee (Kevin)
Número de funcionários305
Tipo de títulosDepository Receipt
Fim do ano fiscalMay 23
EndereçoBlocks A & B, Portway Building
CidadeCAMBRIDGE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited Kingdom
Código postalCB21 6GS
Telefone11441223261503
Sitehttps://www.bicycletherapeutics.com/
Código da empresaBCYC
Data de listagemMay 23, 2019
CEOLee (Kevin)
Executivos da empresa Bicycle Therapeutics PLC
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Kevin Lee, Ph.D.
Dr. Kevin Lee, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
317.14K
+13.10%
Dr. Michael Skynner, Ph.D.
Dr. Michael Skynner, Ph.D.
Chief Technology Officer
Chief Technology Officer
69.97K
-4.22%
Mr. Alistair Milnes
Mr. Alistair Milnes
Chief Operating Officer
Chief Operating Officer
39.58K
+35.99%
Ms. Janice Bourque
Ms. Janice Bourque
Non-Executive Independent Director
Non-Executive Independent Director
25.38K
+27.83%
Dr. Alessandro Riva, M.D.
Dr. Alessandro Riva, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
6.01K
--
Dr. Roger D. Dansey, M.D.
Dr. Roger D. Dansey, M.D.
Independent Director
Independent Director
758.00
--
Mr. Herve Hoppenot
Mr. Herve Hoppenot
Independent Director
Independent Director
758.00
-300.00%
Sir Gregory Winter
Sir Gregory Winter
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Jose Carlos Gutierrez-Ramos, Ph.D.
Dr. Jose Carlos Gutierrez-Ramos, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Alethia R. Young, M.D.
Ms. Alethia R. Young, M.D.
Chief Financial Officer
Chief Financial Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Kevin Lee, Ph.D.
Dr. Kevin Lee, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
317.14K
+13.10%
Dr. Michael Skynner, Ph.D.
Dr. Michael Skynner, Ph.D.
Chief Technology Officer
Chief Technology Officer
69.97K
-4.22%
Mr. Alistair Milnes
Mr. Alistair Milnes
Chief Operating Officer
Chief Operating Officer
39.58K
+35.99%
Ms. Janice Bourque
Ms. Janice Bourque
Non-Executive Independent Director
Non-Executive Independent Director
25.38K
+27.83%
Dr. Alessandro Riva, M.D.
Dr. Alessandro Riva, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
6.01K
--
Dr. Roger D. Dansey, M.D.
Dr. Roger D. Dansey, M.D.
Independent Director
Independent Director
758.00
--
Detalhamento da receita
Os dados relevantes ainda não foram divulgados pela empresa.
Os dados relevantes ainda não foram divulgados pela empresa.
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: sáb, 9 de mai
Atualizado em: sáb, 9 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Baker Bros. Advisors LP
21.68%
Forbion Capital Partners
6.89%
Armistice Capital LLC
6.42%
Acadian Asset Management LLC
3.32%
Long Focus Capital Management LLC
3.24%
Outro
58.45%
Investidores
Investidores
Proporção
Baker Bros. Advisors LP
21.68%
Forbion Capital Partners
6.89%
Armistice Capital LLC
6.42%
Acadian Asset Management LLC
3.32%
Long Focus Capital Management LLC
3.24%
Outro
58.45%
Tipos de investidores
Investidores
Proporção
Hedge Fund
36.92%
Investment Advisor
14.08%
Investment Advisor/Hedge Fund
7.12%
Venture Capital
7.12%
Corporation
3.04%
Individual Investor
1.47%
Research Firm
1.20%
Family Office
0.53%
Pension Fund
0.51%
Outro
28.02%
Participação acionária institucional
Atualizado em: qua, 1 de abr
Atualizado em: qua, 1 de abr
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2026Q1
250
33.87M
67.23%
-23.14M
2025Q4
242
39.22M
114.58%
+31.05K
2025Q3
266
40.06M
126.53%
-4.18M
2025Q2
264
44.22M
123.05%
-338.39K
2025Q1
249
44.93M
127.83%
-16.05M
2024Q4
249
44.97M
130.44%
+273.71K
2024Q3
245
43.83M
123.27%
+876.01K
2024Q2
237
43.44M
106.75%
+5.72M
2024Q1
253
34.16M
113.53%
-14.25M
2023Q4
258
34.56M
124.36%
-3.64M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Baker Bros. Advisors LP
10.92M
21.73%
+38.00K
+0.35%
Jan 02, 2026
Forbion Capital Partners
3.47M
6.9%
+16.10K
+0.47%
Dec 31, 2025
Armistice Capital LLC
3.24M
6.44%
+258.00K
+8.66%
Dec 31, 2025
Acadian Asset Management LLC
1.67M
3.32%
+356.70K
+27.13%
Dec 31, 2025
Long Focus Capital Management LLC
1.63M
3.25%
+214.40K
+15.11%
Dec 31, 2025
Invus Public Equities Advisors, LLC
3.15M
6.26%
+1.14M
+56.45%
Feb 25, 2026
GSK plc
1.53M
3.04%
+1.53M
--
Dec 31, 2025
Principal Global Investors (Equity)
1.15M
2.28%
-130.00
-0.01%
Dec 31, 2025
T. Rowe Price Associates, Inc.
1.17M
2.33%
-213.01K
-15.38%
Dec 31, 2025
Schroder Investment Management Ltd. (SIM)
584.77K
1.16%
+584.77K
--
Dec 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
Virtus LifeSci Biotech Clinical Trials ETF
0.63%
Invesco NASDAQ Future Gen 200 ETF
0.59%
Harbor Health Care ETF
0.23%
ALPS Medical Breakthroughs ETF
0.17%
iShares Health Innovation Active ETF
0.05%
Invesco Nasdaq Biotechnology ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.04%
SPDR S&P International Small Cap ETF
0.03%
iShares Biotechnology ETF
0.02%
ActivePassive International Equity ETF
0%
Ver Mais
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0.63%
Invesco NASDAQ Future Gen 200 ETF
Proporção0.59%
Harbor Health Care ETF
Proporção0.23%
ALPS Medical Breakthroughs ETF
Proporção0.17%
iShares Health Innovation Active ETF
Proporção0.05%
Invesco Nasdaq Biotechnology ETF
Proporção0.04%
ProShares Ultra Nasdaq Biotechnology
Proporção0.04%
SPDR S&P International Small Cap ETF
Proporção0.03%
iShares Biotechnology ETF
Proporção0.02%
ActivePassive International Equity ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
